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Dystrophin absence in Duchenne muscular dystrophy (DMD) causes severe
muscle degeneration. We describe that, as consequence of ﬁbre damage, speciﬁc
muscle-miRNAs are released into the bloodstream of DMD patients and their
levels correlate with the severity of the disease. The same miRNAs are abundant
also in the blood of mdx mice and recover to wild-type levels in animals ‘cured’
through exon skipping. Even though creatine kinase (CK) blood levels have been
utilized as diagnostic markers of several neuromuscular diseases, including DMD,
we demonstrate that they correlate less well with the disease severity. Although
the analysis of a larger number of patients should allow to obtain more reﬁned
correlations with the different stages of disease progression, we propose that
miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis
of DMD and possibly also for monitoring the outcomes of therapeutic interven-
tions in humans. Despite many different DMD therapeutic approaches are now
entering clinical trials, a unifying method for assessing the beneﬁt of different
treatments is still lacking.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is one of the most severe
neuromuscular diseases and affects 1:3500 live males. DMD is a
monogenic disorder caused by mutations in the 2.5Mb-long
dystrophin gene (DMD). Deletions/duplications and point
mutations in this gene cause either the severe Duchenne
phenotype (DMD) or the milder Becker muscular dystrophy
(BMD), depending on whether the translational reading frame is
lost or maintained (Hoffman et al, 1988).
Dystrophin (DYS) is localized on the inner face of the muscle
ﬁbre plasma membrane, linking cytoskeletal actin with a
complex of proteins localized on the sarcolemma, named DYS-
associated protein complex (DAPC). In the absence of DYS,
muscle ﬁbres become more sensitive to mechanical damage
leading to muscle degeneration, chronic inﬂammation and
increase in ﬁbrosis, exacerbating the dystrophic phenotype. All
these traits are clearly attenuated in Becker patients with a mild
myopathic phenotype (Monaco et al, 1988).
In boys under 5 years, diagnostic investigation is usually
triggered by the presence of abnormal muscle function
manifested by Gowers’ sign, calf hypertrophy, toe walking,
andwaddling gait. WhenDMD is suspected, theﬁrst assessment
is the measurement of serum creatine kinase (CK) levels, which
are markedly increased in early stages of the disease (10–100
fold higher than healthy controls; Ebashi et al, 1959). Genetic
diagnosis is currently assessed by different diagnostic proce-
dures: multiplex polymerase chain reaction (PCR) assay for the
identiﬁcations of deletions that account for 65% of DMD
patients(Chamberlainetal,1988);multiplexligation-dependent
probe ampliﬁcation that also allows identiﬁcation of insertions
(Schouten et al, 2002); Southern blotting (Stockley et al, 2006)
or multiplex ampliﬁable probe hybridization (Dent et al, 2005).
If the mutation remains unidentiﬁed, DMD sequencing is
required to ﬁnd point mutations or small insertions/deletions
(Stockley et al, 2006).
Several strategies have been recently set up in order to rescue
DYS synthesis in animal models of DMD (Aartsma-Rus and van
Ommen, 2010; Cossu & Sampaolesi, 2007) and some of them
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One of the major problems in comparing the beneﬁt of
different therapeutic treatments is to ﬁnd common outcome
measurements. The serum CK values are not reliable since they
do not correlate with clinical assessments measured through
magnetic resonance imaging (MRI; Kim et al, 2010). Moreover,
CKlevels areinﬂuenced by theage ofthechild(Zatz etal, 1991),
by pharmacological treatments that do not have any effect on
functional status and are increased by physical activity (Malm
et al, 2000).
In this work, we showed that microRNAs, speciﬁcally
expressed in muscle cells, were released into the blood of
DMD patients as a consequence of muscle degeneration and
their amount paralleled the severity of the disease. Notably,
increased serum levels of muscle-speciﬁc miRNAs were also
found in the animal model of DMD, the mdx mice, and
these levels were lowered to almost wild-type (WT) values in
animals treated with exon skipping, known to restore DYS
synthesis and ﬁbre integrity (Denti et al, 2006a, 2006b, 2008).
Comparison between miRNA and CK measurements, both in
DMD patients and mdx mice, indicated that miRNAs better
correlate with DMD severity and suggest that they can be
possibly utilized for measuring the outcomes of different
therapeutic interventions.
RESULTS
Muscle miRNAs are enriched in the serum of DMD patients
Serum samples from healthy, Becker, and Duchenne children,
ranging between 1- and 16-years-old, were collected under
informed consensus. Prior to RNA extraction, a cocktail of
artiﬁcial spiked miRNAs (ath-miR-159a, cel-lin-2, and cel-lin-4)
was added to each sample in order to normalize raw data for
qRT-PCR efﬁciency and for variability in volume handling. qRT-
PCR was performed with probes for the muscle-speciﬁc miR-1,
miR-206, and miR-133 as well as for the spikes. For mir-133, a
single probe recognizing both miR-133a and miR-133b isoforms
was utilized. Quantiﬁcation of the granulocyte-speciﬁc miR-223
was utilized as control (Fazi et al, 2005). Figure 1A shows that
all three miRNAs are almost undetectable in the serum of
healthy controls (less than 10^3copies/ml). A moderate
enrichment (between 10^3 and 10^4copies/ml) was detected
in BMD individuals while a considerable increase was found in
DMD patients (up to 10^6copies/ml). In the different samples,
no signiﬁcant differences in the levels of miR-223 were
observed. The same results were also obtained from whole
blood RNA preparations (not shown). The statistical signiﬁ-
cance of these measurements was conﬁrmed by receiver
operating characteristics (ROC) analysis (Fig 1B) obtained by
plottingtherateoftruepositive(sensitivity) versusfalsepositive
(1-speciﬁcity). These results show that miR-206 is able to
discriminate DMD from WT (healthy) and BMD cases with
almost absolute speciﬁcity (AUC always >0.94, p<0.001) but
also miR-1 and miR-133 display a very good statistical score
(AUC always >0.84 and >0.76, respectively, p<0.01).
Serum miRNA levels correlate with clinical assessments
To study whether miR-1, miR-133, and miR-206 could represent
bona ﬁde markers for DMD, a case-by-case correlation analysis
between miRNA levels and North Star Ambulatory Assessment
(NSAA, Mazzone et al, 2010) was performed in 10 ambulating
young DMD children (age range between 3 and 6 years) at the
time of the molecular diagnosis. NSAA is one of the actual ‘gold
standard’ functional tests to score DMD motor ability (from
value 34 – normal ambulation, to value 0 – absence of
ambulation). Figure 2A shows an inverse correlation between
miRNA levels and NSAA score indicating that a progressive
decrease in NSAA is associated with a gradual increase in
miRNA serological levels. Figure 2B shows Spearman correla-
tionbetweenmiRNAandNSAA,whichissigniﬁcantforallthree
miRNAs (the shown p-values are always <0.05). In addition, a
direct correlation between miRNA levels and age is observed as
well as a correlation between age and NSAA, as previously
reported (Mazzone et al, 2010). Interestingly, patient DMD10,
coetaneous with DMD9 but with worst motor ability (NSAA 16
and 25, respectively), displays a 26-fold increase of miRNA
levels in comparison to DMD9 (right panel of Fig 2A). This
speciﬁc case is quite interesting since it suggests that,
independently from age, the increase in miRNA levels correlates
with the severity of muscle damage. In contrast to miRNAs,
which show a very clear inverse correlation with NSAA scores,
the CK values show ﬂuctuations unrelated to the severity of the
disease (Fig 2A, lower panel).
The situation in older, not ambulant patients, is more
complicated due to heterogeneous clinical conditions and to the
progressive loss of muscle mass. This can have strong effects on
the amount of muscle cellular material released into the blood,
as previously described for CK (Zatz et al, 1991). In agreement
with this, in older patients, we observed a decrease of serum
miRNA levels, even though they were still higher than samples
from healthy controls (supplementary Fig 1).
miRNAs as biomarkers for therapeutic outcome
measurements
Six-week-old mdx animals were tail vein injected with a
recombinant adeno-associated viral vector carrying a U1-
chimeric antisense construct (AAV#23, Fig 3A), previously
reported to induce the skipping of the mutated exon 23 and to
restore DYS synthesis and morpho-functional beneﬁt in a body-
wide manner (Denti et al, 2006a). After 1 month, mdx and
AAV#23-treated mdx siblings were sacriﬁced in parallel with
WT isogenic/aged matched animals. Different muscular dis-
tricts [gastrocnemius (GAS), diaphragm (DIA), and heart
(HEA)] were collected together with sera. Western blot revealed
that through the exon skipping treatment, rescue of DYS was
obtained (representative muscle districts are shown in Fig 3B),
conﬁrming the previously described body-wide activity of the
AAV#23 virus. Moreover, the AAV#23 administration resulted
in morphological amelioration of muscle ﬁbres (Fig 3C) in
agreement with our previous ﬁndings (Denti et al, 2006a, 2008).
qRT-PCR for miR-1 and miR-206 in serum indicated that these
miRNAsare20/40-foldenrichedinmdxwithrespecttoWTmice
(Fig 3D). Notably, the levels of these miRNAs are rescued to
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Figure 1. Differential amounts of muscle miRNAs in the sera of healthy versus dystrophic children.
A. Boxplots comparing microRNA levels in theseraof7 healthy, 26Duchenne(DMD), and5 Becker (BMD) patients (patientinformationis listedin supplementary
Table 1). All data were normalized for three spiked miRNAs (ath-miR-159a, cel-lin-2, and cel-lin-4). miR-1, miR-206, and miR-133 values are shown as copy
number per ml of serum. Control miR-223 levels are also shown as fold change values. All values are shown in logarithmic scale. p-values are derived from the
comparison of miRNA levels in DMD or BMD versus healthy patients.
B. ROC curves regarding diagnostic power to distinguish healthy from dystrophic cases. Area under the curve (AUC) values are also shown.
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Figure 2. Correlation between clinical assessment and serum miRNAs.
A. Case-by-case comparison of miRNA levels and CK values with NSAA in 10 DMD children between 3 and 6 years of age (patient information is listed in
supplementaryTable1).Ineachgraph,miRNAlevelsareshownaswhitedots(copynumbers/mlofserum),NSAAscoresasblackdots,andCKvalues(units/mlof
serum) as diamonds; regression lines are also displayed. Patients DMD 1–3, due to their age (3 years), have a non-collaborative behaviour to perform theentire
NSAA; however, all of them had normal muscle strength at neurological assessment and they are indeed indicated with maximum NSAA score according to
normal ambulation. For the outlier patient DMD10, different scales were used (graphs on the right).
B. Spearman analysis correlating miRNA or CK levels with age or NSAA scores in DMD children. In the two tables, Spearman coefficients (R)a n dp-values (p) are displayed.
www.embomolmed.org EMBO Mol Med 3, 258–265  2011 EMBO Molecular Medicine 261almost WT levels in AAV#23-treated mdx mice. In comparison
to miRNA quantiﬁcations, CK titration reveals a mild increase in
mdx mice, with respect to WT, without relevant statistical
signiﬁcance (Fig 3D, right panel). Altogether, these results
indicate that the recovery of muscle integrity as a consequence
of exon skipping is accompanied by a drastic decrease in miRNA
release in the bloodstream. The conspicuous release of miR-1
and miR-206 observed in mdx conditions was also conﬁrmed in
WT animals treated with cardiotoxin, a drug normally used to
induce acute muscle damage (not shown).
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Figure 3. Muscle miRNAs (dystromiR) as diagnostic markers for DMD gene therapy.
A. Schematic representation of the exon skipping strategy in mdx mice (Denti et al, 2006a).
B. Westernblotfordystrophin(DYS)andactinin(ACTN)perfomedwith50mgofmuscleextracts(GAS,gastrocnemius;HEA,heart;DIA,diaphragm)ofWT,mdxand
AAV-U1#23 treated mdx (AAV#23). In control lane (wild-type; WT), 5mg of WT protein extract were mixed with 45mgo fmdx proteins in order to avoid signal
saturation.
C. Mdx gastrocnemius sections from untreated (mock) or exon skipping-treated (AAV#23) animals were analysed by Hematoxylin/Eosin staining. Original
magnification 20 . Scale bar: 100mm.
D. Box plots comparing microRNA and CK levels in the serum of WT, mdx, and AAV#23-treated mdx mice. miRNA values were normalized for three spiked miRNAs
(ath-miR-159a, cel-lin-2, and cel-lin-4). All data are shown as fold change values with respect to WT set to a value of 1. p-values are derived from the
comparison between miRNA or CK levels in mdx versus WT animals.
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It has been recently reported that miRNAs expressed in speciﬁc
body compartments can be released into the blood as a
consequence of different types of injuries and that they can
represent sensitive biomarkers for several diseases, including
cancer (Scho ¨ler et al, 2010). The surprisingly high stability of
miRNAs in the serum was explained by the observation that
miRNAs could be part of exosomal particles (Mitchell et al,
2008).
Since intense degeneration occurrs in many neuromuscular
disorders, including DMD, we tested whether muscle miRNAs
could be released in the serum, representing sensitive markers
of muscle degeneration.
Several miRNAs have been shown to be speciﬁcally
expressed in muscle cells and to play a very crucial role in
the control of proper muscle development and function (Crist &
Buckingham, 2009, 2010; van Rooij et al, 2008a). Moreover,
altered levels of miRNAs were found in several muscular
disorders such as myocardial infarction (van Rooij et al, 2008b),
DMD, and other myopathies (Eisenberg et al, 2007). In
particular, miR-1 and miR-133, highly abundant in mature
muscle ﬁbres, were found at reduced levels (two-fold) both in
human and mouse dystrophic myoblasts (Cacchiarelli et al,
2010). In this study, we show that miR-1 and miR-133 are
highly abundant in the bloodstream of DMD patients
despite their reduced synthesis in dystrophic muscles: almost
100-fold enriched in comparison to samples from healthy
controls, and 5–10 fold enriched with respect to BMD
individuals.
At variance with miR-1 and miR-133, the levels of miR-206
are doubled in dystrophic versus WT muscles (Cacchiarelli et al,
2010). This was shown to be due to its speciﬁc expression in
activated satellite cells and proliferating myoblasts, more
numerous in dystrophic muscles where intense regeneration
occurs. However, the 30- and 100-fold increase in respect
to control, found, respectively, in the serum of BMD and
DMD patients, cannot simply reﬂect the increase of miR-206
in DMD ﬁbres. Overall, these results allowed us to conclude
that the differences in serum levels of these miRNAs derive
from the intensive degeneration occurring in DMD muscles.
In agreement with previous observations in dystrophic
young dogs (Cozzi et al, 2001), intense degeneration occurs
not only in mature ﬁbres, but also in miR-206-enriched
immature ﬁbres determining the observed miR-206 release in
the bloodstream.
Interestingly, when comparing the levels of serum miRNAs
with the functional performances of DMD patients, we
observed a very good inverse correlation: high levels of
miRNAs corresponded to low ambulant activity. Notably,
miRNA quantiﬁcation was a better diagnostic marker than
CK activity, which displays ﬂuctuations unrelated to the
severity of the disease. A further advantage of miRNA
detection relates to the fact that CK activity is very sensitive
to stress conditions and has to be measured in fresh serum
preparations, while the serum stability of miRNA is very long
lasting (Mitchell et al, 2008). Our analyses were performed on
young ambulant patients (<6y e a r s )s i n c eav e r yw e l l
established and reliable clinical assessment for the quantiﬁca-
tion of disease severity (NSAA) is available (Mazzone et al,
2010).
For non-ambulating patients, whose NSAA reaches the
lowest score, there are indicators like muscle measurements,
fat and ﬁbrous tissue deposition measured by MRI (Kim et al,
2010). Unfortunately, no uniform functional, non-invasive tests
to evaluate disease progression are available.In future work, we
plan to extend our analysis to a large number of such ‘old’ cases
in order to deﬁne whether we can establish reference values
for testing: (i) whether miR-206 levels (speciﬁcally expressed
in precursor muscle cells) can be utilized to establish the
regenerating potentiality of the patients and (ii) whether miR-1
and miR-133 levels represent indicators of the residual muscle
mass.
The results obtained from patients were conﬁrmed in the
animal model of DMD, the mdx mouse. In particular, in 2-
month-old animals, both miR-1 and miR-206 were more
abundant (38 and 23-fold, respectively) in the serum ofmdxin
comparison to WT controls. The mdx model allowed us to
study whether muscle miRNAs can be also exploited as
biomarkers for studying the recovery of muscle integrity upon
therapeutic interventions. Nowadays, several strategies have
been developed for the cure of DMD (Aartsma-Rus & van
Ommen, 2010; Cossu & Sampaolesi, 2007) and among them,
exon skipping has proved to be very promising. Indeed, two
clinical trials of phase I have been recently concluded using
different kinds of modiﬁed-antisense oligonucleotides (Kinali
et al, 2009; van Deutekom et al, 2007). Exon skipping is
effective in the mdx mice where, through the use of AAV
vectors expressing U1-snRNA antisense molecules, efﬁcient
rescue of DYS was obtained together with recovery of correct
tissue morphology and integrity (this work and Denti et al,
2006a, 2006b, 2008). In these mice, recovery of DYS
paralleled the decrease of serum muscle miRNAs to almost
WT levels. Notably, a partial recovery of DYS (<10%;
Cacchiarelli et al, 2010; Denti et al, 2006a, 2008) was able
to produce amelioration of morpho-functional parameters
and to reduce serum levels of muscle miRNAs. Also in mouse
sera, CK titration failed to accurately discriminate WT from
mdx mice.
Even though a larger collection of data from DMD patients
will be required in order to establish a precise correlation
between miRNA levels, extent of muscle degeneration and
stage of the disease (age, ambulating conditions, and time
since wheel chair use), our studies indicate that the
quantiﬁcation of speciﬁc miRNAs (dystromiR), or even of
only one of them, in serum, can be utilized as a biomarker tool
to reveal DMD conditions in humans. In consideration of the
results with mdx mice ‘cured’ through exon skipping, we
propose to test whether this method can be applied to measure
the outcomes and effectiveness of different therapeutic
interventions. This seems particularly useful since, even
though several therapeutic approaches are now entering
clinical trials, a unifying method for assessing the beneﬁt of
the different treatments is still lacking.
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Patient inclusion criteria
The study was approved by the local Ethical Committee and sera
were obtained under informative consensus. Patient inclusion
criteria were: genetically proven DMD or BMD diagnosis, patient
still ambulant without any help (only for children younger than
6-years-old), no severe or moderate learning difficulties or
behavioural problems.
Animal treatments and analyses
Six-week-old mdx mice were tail vein injected with 0.5–1 10^12
genome copies of the AAV-U1#23 virus (AAV#23). After 1 month, mdx
and AAV#23-treated mdx siblings were sacrificed in parallel with WT
isogenic/aged matched animals. The above procedures including H&E
staining and Western blot analyses are fully described in Denti et al
(Denti et al, 2008).
RNA preparation and analysis
Serum was harvested from patients or mice by centrifugation of blood
in serological tubes. Prior to RNA extraction, 1fmole of three spiked
artificial miRNAs (ath-miR-159a, cel-lin-2 and cel-lin-4) was added
each 150ml of serum (300ml for patients – 50ml for mice). Small
RNAs were extracted by miRNeasy (Qiagen), following manufacturer
specifications for liquid samples. qRT-PCR were performed using
miScript System (Qiagen). Copy number analyses were performed by
using standard curves from artificial templates normalized for
absolute quantifications obtained from miRNA-spiked.
Statistical analyses
Each data shown in qRT-PCR analysis is the result of at least five
independent experiments performed on at least five different samples
of the same group. Box Plots are produced indicating median (–, inside
the box) first and third quartiles (box borders), minimum and
maximum (–, outside the box). Statistical significance of differences
between distributions was assessed by two-tailed t-test and a
p<0.05 was considered significant. In Fig 1A the Welch t-test was
applied. ROC curves are produced by plotting sensitivity versus 1-
specificity for 28 different thresholds (Søreide, 2009). Relationship
between variables was calculated using the Spearman correlation
coefficient (indicated as R in the text). A correlation >0.75 was
considered as an acceptable relationship and a p<0.05 was
considered significant.
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The paper explained
PROBLEM:
Duchenne muscular dystrophy (DMD) is a severe genetic disease
caused by the lack of functional dystrophin (DYS). Nowadays,
several strategies have been developed for the cure of DMD and
among them, exon skipping has proved to be very promising.
Indeed, two clinical phase I trials have recently been concluded
using different kinds of modified-antisense oligonucleotides. In
addition, exon skipping has proved to be very effective as a gene
therapy treatment: in the mdx mice, efficient rescue of DYS was
obtained together with recovery of correct tissue morphology
and integrity through the use of AAV vectors expressing
U1-snRNA antisense molecules. Such molecules have recently
obtained the Orphan Drug designation from EMEA and FDA.
RESULTS:
DYS absence in DMD causes intense muscle degeneration. CK
blood levels have been utilized as diagnostic markers of several
neuromuscular diseases, including DMD. However, CK levels
are not reliable since they vary considerably upon several
independent stress conditions, not necessarily associated with
disease. In this work, we describe a new method formeasuring
the onset and progression of DMD: we identified three muscle
miRNAs that, as a consequence of muscle damage, are released
into the bloodstream. Moreover, their abundance was described
to correlate with the severity of the disease.
IMPACT:
Since in mdx mice cured with exon skipping, the levels of serum
miRNA recovered to WT levels, we propose that these miRNAs
represent valuable biomarkers not only for the diagnosis of DMD
onset and progression but also for monitoring the outcomes of
therapeutic interventions on humans. Even though many
different DMD therapeutic approaches are now entering clinical
trials, a unifying method for assessing the benefit of different
treatments is still lacking.
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